Ask anyone who has battled their weight all their life (yours truly included), and you’ll discover the staggering amount of time, energy, and mental bandwidth that mere weight management consumes. On paper, fitness is simple: “Eat less and move more.” Easy, right?
Except it isn’t.
Because “eat less” really means eat less than you want to, all the time—and “move more” means move more than any normal human being would voluntarily choose to. Add to this our environment, where tempting, hyper-delicious foods follow us around like loyal but toxic best friends—whether marketed by brands or lovingly forced upon us by Indian relatives.
Indians don’t say “I love you.”
They say, “Beta, have one more samosa.”
Our national love language is food—preferably the fat-carb-sugar explosion called mithai or the fat-carb-salt bomb known as namkeen. The most common expression of care in India is “Did you eat?” Nobody ever asks, “Did you eat less, like you’re supposed to?”
And the “move more” part? Harder still. Trillion-dollar tech companies have trapped us in the quicksand of reels, videos, and binge-worthy content. Exercise culture is patchy—some walking, some yoga, all inconsistent. Step outside and you face pollution, traffic, street dogs, and roads that treat pedestrians as an optional feature. Even kids don’t play outside anymore; why run in a park when an iPad can do the running for you?
The result: millions of overweight Indians who simply cannot eat less and move more. Long ago, India’s biggest challenge was lack of food; now, for a huge section of society, the opposite problem is just as serious—too much food, too little movement, and a culture that reinforces both.
And then something big happened in 2025. Something that, if global trends are any indication, is about to completely transform India over the next few years.
GLP-1 drugs arrived.
These drugs are expensive and require weekly self-injections. Despite that, within months of launch, they shot up the sales charts. Why? Because GLP-1s actually help people lose weight — genuinely. Weight-loss solutions have always been a huge opportunity, and we’ve seen everything: dangerous pills, risky bariatric surgeries, vibrating belts, herbal gimmicks — most of them ineffective or unsafe. But nothing in the last 50 years has shown results like GLP-1s.
Skepticism is understandable. Over the decades, we’ve seen vibrating belts, “fat-melting” oils, electromagnetic waistbands (spoiler: also useless), herbal supplements (double useless), and drastic solutions like bariatric surgery. But nothing in the last 50 years has shown results quite like GLP-1s. Millions of users, multiple large studies—verdict: they work.
So what exactly are GLP-1s? GLP-1 stands for glucagon-like peptide-1, a hormone that regulates appetite and blood sugar. These drugs mimic the hormone, reduce cravings, lower blood sugar, and help with weight loss. They’re so potent that tiny milligram doses can cross the blood–brain barrier and directly activate satiety centers in the brain.
Fun fact: research on these drugs began with the Gila monster, a lizard that eats once or twice a year. So yes, you are technically taking weight-loss advice from a reptile.
Today, these medicines appear under names like Ozempic, Wegovy, Mounjaro, and Zepbound. Some variations target different hormones; some were first approved for diabetes or sleep apnea. But now they’re at a chemist near you—selling faster than samosas and jalebis.
Example: Eli Lilly launched Mounjaro in India in May 2025. By October, it was the highest-selling drug in India by value, crossing ₹100 crore ($11 million) in a single month. Globally, Lilly made a jaw-dropping $25 billion (or Rs 2 lakh crore!) from Mounjaro and Zepbound in the first nine months of 2025. Their market cap crossed $1 trillion—the first pharma company ever to do so. Surveys show that 1 in 8, or 12% of adults in the U.S. has already tried GLP-1s. Food companies there are literally predicting nationwide reduced food demand because of these drugs.
Is India headed the same way? My bet: absolutely.
GLP-1s are cheaper here but still pricey—around ₹13,000 for four weekly injections. Not exactly pocket change. But several patents expire in 2026, and affordable Indian versions are already in development. Soon, lakhs—if not millions—of samosa- and gulab-jamun-loving Indians will give these injections a try. Expect a social revolution in the next three years.
But is this a magic bullet? Does “eat less, move more” now become “eat biryani daily, inject once a week”?
Not quite.
These drugs have side effects—nausea, constipation, indigestion, and general stomach drama. And they absolutely do not replace healthy eating or exercise. At best, they suppress hunger, making it easier to follow a sensible diet. Exercise remains essential—not just for calorie burn, but to prevent muscle loss. Without movement, you may lose weight—but at the cost of muscle, which is a terrible trade, especially as we age.
The smart approach is using the lowest effective dose to quiet the “food noise”—the constant internal commentary that says “Bhujia? Biscuits? Pao bhaji?” every 12 minutes.
But of course, many people will misuse the drugs—skipping exercise, eating poorly, and expecting miracles. They’ll end up with muscle loss and the dreaded “Ozempic face”—a hollow, shrivelled look that even Instagram filters can’t fix.
There’s another catch: stop the drug, and hunger comes roaring back. If you haven’t learned better food habits while on it, you will gain back all the weight—and possibly even more. That’s not speculation; studies confirm it.
So yes, these drugs have great uses. But here’s what they are not:
They are not substitutes for discipline.
They are not shortcuts to a six-pack.
They will not let you recline on a sofa, binge-watch TV, and still lose weight while polishing off samosas and jalebis.
Nature demands effort. It rewards discipline—not injections—with long-term health. For now, no drug can give you a ripped body without work. Maybe AI will crack that someday, but for now, the old rule stands: move your body, eat sensibly, and build discipline.
Discipline may never be a trillion-dollar company, but when it comes to living a good life, it is—and will always be—priceless.